protein phosphatase 2 scaffold subunit AbetaGenealiases: PP2A-Abeta · PR65B
Q-omics provides the consensus-scored PPP2R1B profile across patient tissues and cancer cell-line models. PPP2R1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPP2R1B is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, PPP2R1B RNA expression shows 19,191 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where PPP2R1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2R1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2R1B survival associations across molecular data types. PPP2R1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2R1B RNA expression–survival associations across cancer types. High PPP2R1B expression shows unfavorable associations in LGG, BLCA, MESO and ACC, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPP2R1B RNA expression.
This table summarizes PPP2R1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PPP2R1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2R1B shows lower tumor expression in THCA and BRCA and higher tumor expression in BLCA, HNSC, LUAD and STAD. The BLCA box plot shows higher PPP2R1B RNA expression in tumor versus normal tissue (log2 FC = +0.730, t-test p < 0.001).
This table shows molecular features associated with PPP2R1B in patient tissues and cancer cell lines. In patient samples, PPP2R1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP2R1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
